Sarepta Therapeutics Inc Stock Nasdaq
Equities
US0023461041
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Financials (USD)
Sales 2024 * | 1.8B | Sales 2025 * | 2.9B | Capitalization | 10.94B |
---|---|---|---|---|---|
Net income 2024 * | 189M | Net income 2025 * | 997M | EV / Sales 2024 * | 5.47 x |
Net cash position 2024 * | 1.07B | Net cash position 2025 * | 2.58B | EV / Sales 2025 * | 2.88 x |
P/E ratio 2024 * |
54
x | P/E ratio 2025 * |
11.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.22% |
Latest transcript on Sarepta Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
Ian Estepan
DFI | Director of Finance/CFO | 48 | 14-12-31 |
Bilal Arif
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
M. Wilsey
CHM | Chairman | 71 | 09-03-30 |
Richard Barry
BRD | Director/Board Member | 65 | 15-06-01 |
1st Jan change | Capi. | |
---|---|---|
-3.07% | 102B | |
+1.68% | 96.07B | |
-1.80% | 21.66B | |
-17.59% | 20.77B | |
-6.91% | 18.53B | |
-40.31% | 16.91B | |
-27.94% | 13.79B | |
+0.07% | 13.33B | |
-22.37% | 8.57B |